Guanidinium l-glutamate.

Department of Applied Chemistry, China Agricultural University, Yuanmingyuan, West Road 2, Haidian District, Beijing 100194, People's Republic of China.
Acta Crystallographica Section E Structure Reports Online (Impact Factor: 0.35). 01/2010; 66(Pt 10):o2679. DOI: 10.1107/S1600536810036354
Source: PubMed

ABSTRACT In the title compound, CH(6)N(3) (+)·C(5)H(8)NO(4) (-), there are two independent cations and two independent anions in the asymmetric unit. In the crystal structure, cations and anions are linked by inter-molecular N-H⋯O hydrogen bonds into a three-dimensional network.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Salification of new drug substances in order to improve physico-chemical or solid-state properties (e.g. dissolution rate or solubility, appropriate workup process, storage for further industrial and marketing development) is a well-accepted procedure. Amino acids, like aspartic acid, lysine or arginine take a great part in this process and are implicated in several different formulations of therapeutic agent families, including antibiotics (amoxicillin from beta lactam class or cephalexin from cephalosporin class), NSAIDs (ketoprofen, ibuprofen and naproxen from profen family, acetylsalicylic acid) or antiarrhythmic agents (e.g. ajmaline). Even if more than a half of known pharmaceutical molecules possess a salifiable moiety, what can be done for new potential drug entity that cannot be improved by transformation into a salt? In this context, after a brief review of pharmaceutical salts on the market and the implication of amino acids in these formulations, we focus on the advantage of using amino acids even when the target compound is not salifiable by exploiting their zwitterionic potentialities for cocrystal edification. We summarize here a series of new examples coming from literature to support the advantages of broadening the application of amino acids in formulation for new drug substances improvement research for non-salifiable molecules.
    European journal of medicinal chemistry 01/2014; 74C:411-426. · 3.27 Impact Factor

Full-text (2 Sources)

Available from
Jun 10, 2014